VeonGen与FDA就Stargardt病基因疗法VG801关键性3期设计达成一致
VeonGen Aligns with FDA on Phase 3 Design for Stargardt Gene Therapy
VeonGen Therapeutics于2026年11月5日宣布,已与FDA就VG801治疗Stargardt病及其他ABCA4相关视网膜营养不良的关键性3期设计和生产策略达成一致。
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
VeonGen Therapeutics announced on November 5, 2026, that it has reached alignment with the FDA on the pivotal phase 3 design and manufacturing strategy for VG801, its investigational dual-adeno-associated virus (AAV) gene therapy for Stargardt disease and other ABCA4-associated retinal dystrophies.¹ The company also reported that VG801 produced sustained functional vision improvements through month 12 in its ongoing phase 1/2 study.¹
Key facts
- Drug: VG801 (VeonGen Therapeutics)
- Class: dual-AAV gene therapy (vgAAV2 capsid plus vgRNA REVeRT)
- Target gene: ABCA4
- Indication: Stargardt disease and ABCA4-associated retinal dystrophies
- Trial: NCT07002398; phase 1/2, first-in-human; 15 patients dosed
- Efficacy: 11 of 13 evaluable patients gained ≥5 ETDRS letters
- Regulatory: FDA alignment on pivotal phase 3 design and CMC strategy
- Designations: RMAT, rare pediatric disease, orphan drug (FDA)
- Unmet need: no approved treatments for Stargardt disease
"FDA alignment on the pivotal Phase 3 clinical and CMC strategy represents an important de-risking milestone for VG801 and a significant step toward global pivotal development," said Caroline Man Xu, PhD, co-founder and CEO of VeonGen Therapeutics.¹
What did the FDA alignment cover?
VeonGen reached alignment with the FDA at a regenerative medicine advanced therapy (RMAT) Type B meeting on key clinical and chemistry, manufacturing, and controls (CMC) aspects of the VG801 pivotal phase 3 program.¹ According to the company, the meeting minutes document alignment on the pivotal study design, including the primary endpoint, study duration, and control arm.¹ On CMC, the alignment covers use of the existing clinical batch for the pivotal study and key aspects of the commercial manufacturing strategy.¹
VeonGen is also advancing the Virtual Reality Visual Test (VRVT) through the FDA's Rare Disease Endpoint Advancement pilot program to support its development as a functional vision measure in Stargardt disease.¹ VG801 has received phase 1/2 clinical trial authorizations in Europe and China.¹
What did the phase 1/2 data show?
The first-in-human phase 1/2 study (NCT07002398) has dosed 15 patients across 3 dose cohorts, including adults and pediatric patients.¹,² VeonGen reported consistent functional improvements through month 12 across best-corrected visual acuity (BCVA), VRVT, and microperimetry fixation.¹
Among the 13 patients with measurable baseline BCVA, all showed improvements from baseline to month 6 or month 12.¹ Of those, 11 achieved gains of at least 5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, including 7 who gained at least 10 letters and 4 who gained at least 15 letters.¹ The company said these findings, along with stable retinal structures and a favorable safety profile to date, support the therapy's potential.¹
How does VG801 work?
VG801 combines VeonGen's vgAAV2 capsid with its vgRNA REVeRT (Reconstitution Via mRNA Trans-splicing) technology to deliver and reconstitute a full-length functional human ABCA4 gene in retinal photoreceptor cells.¹ Because the ABCA4 gene exceeds the cargo limit of a single AAV vector, the dual-AAV approach splits the gene across 2 vectors and joins the fragments at the messenger RNA level through trans-splicing.³ VeonGen said the design is intended to address the genetic cause of Stargardt disease across different ABCA4 mutations, offering a potentially genotype-agnostic approach.¹ VG801 holds FDA RMAT, rare pediatric disease, and orphan drug designations.¹
Why does VG801 matter for Stargardt disease?
Stargardt disease is one of the most common inherited macular dystrophies, affecting an estimated 1 in 8000 to 10,000 people worldwide.¹ Caused by mutations in the ABCA4 gene, it leads to progressive central vision loss that often begins in childhood or adolescence and can progress to legal blindness.¹ There are no approved treatments for the disease.¹
What are the limitations?
The functional improvements come from a small, open-label, first-in-human study without a control arm, and 13 patients were evaluable for BCVA. Detailed results have not been published in a peer-reviewed journal. RMAT alignment on a pivotal design does not guarantee a successful trial or approval, and the controlled phase 3 study has not begun. VeonGen did not disclose the planned phase 3 primary endpoint, study duration, or enrollment.
References
- VeonGen Therapeutics. VeonGen announces FDA alignment on pivotal Phase 3 development and clinical progress of VG801 for Stargardt disease. Press release. Published November 5, 2026. Accessed November 5, 2026. https://www.globenewswire.com/news-release/2026/11/05/3396355/0/en/veongen-announces-fda-alignment-on-pivotal-phase-3-development-and-clinical-progress-of-vg801-for-stargardt-disease.html
- Safety and preliminary efficacy of VG801 in patients with ABCA4 mutation-associated retinal dystrophy (Stargardt disease). ClinicalTrials.gov; NCT07002398. Updated September 2, 2026. Accessed November 5, 2026. https://clinicaltrials.gov/study/NCT07002398
- Riedmayr LM, Hinrichsmeyer KS, Thalhammer SB, et al. mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy. Nat Commun. 2023;14(1):6578. doi:10.1038/s41467-023-42386-0
Related to this article
November 3rd, 2026
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
November 5th, 2026
Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.
November 4th, 2026
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
October 29th, 2026
The proposed FDA guidance would let sponsors add patient-specific gene editing variants to approved BLAs via in vitro data, with comments due November 27, 2026.
November 4th, 2026
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
November 3rd, 2026
Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
November 2nd, 2026
CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
November 2nd, 2026
Inovio reports that Voceryq spared 27% of adults with recurrent respiratory papillomatosis from surgery for 12 months in a 26-patient efficacy group.
来源:BioPharm International · biopharminternational.com







